- Looking beyond the cancer cell for effective drug combinationsJonathan R Dry
Oncology Innovative Medicines and Early Development, AstraZeneca, R and D Boston, Waltham, MA, 02451, USA
Genome Med 8:125. 2016..In this Opinion article, we discuss preliminary work in this area and the needs-in terms of both computational and data requirements-that will truly empower such combinations...
- Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)Jonathan R Dry
Cancer Bioscience, DECS, and Clinical Biomarker Group, AstraZeneca R and D, Alderley Park, Macclesfield, United Kingdom
Cancer Res 70:2264-73. 2010..These signatures offer useful tools for the study of MEK biology and clinical application of MEK inhibitors, and the novel approaches taken may benefit other targeted therapies...